2. Academic Validation
  3. Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy

Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy

  • Curr Opin Pediatr. 2014 Feb;26(1):19-28. doi: 10.1097/MOP.0000000000000046.
Piotr Czauderna 1,  Dolores Lopez-Terrada,  Eiso Hiyama,  Beate Häberle,  Marcio H Malogolowkin,  Rebecka L Meyers
Affiliations

Affiliation

  • 1 aDepartment of Surgery and Urology for Children and Adolescents, Medical University of Gdansk, Gdansk, Poland bDepartment of Pathology, Texas Children's Hospital and Baylor College of Medicine, Houston, Texas, USA cDepartment of Surgery, Natural Science Center for Basic Research and Development, Hiroshima University Hospital, Hiroshima, Japan dChildren's Hospital, Ludwig-Maximilians-University, Munich, Germany eDepartment of Pediatric Hematology and Oncology, Children's Hospital of Wisconsin, Milwaukee, Wisconsin fDepartment of Pediatric Surgery, Primary Children's Medical Center, University of Utah, Salt Lake City, Utah, USA.
PMID: 24322718 DOI: 10.1097/MOP.0000000000000046
Abstract

Purpose of review: As a rare pediatric tumor, hepatoblastoma presents challenges to the individual practitioner as no center will see more than a handful of cases each year.

Recent findings: The Children's Hepatic tumor International Collaborative (CHIC) effort has fostered international cooperation in this rare children's tumor, leading to the establishment of a large international collaborative dataset, the CHIC database, which has been interrogated to refine risk stratification and inform treatment options. Apace with this effort has been the international collaboration of pediatric pathologists working together to establish a new international histopathologic consensus classification for pediatric liver tumors as a whole, with particular focus on the histological subtypes of hepatoblastoma.

Summary: International collaborative efforts in hepatoblastoma have led to a new international histopathologic consensus classification, refinements in risk stratification, advances in chemotherapy, and a better understanding of surgical resection options forming the foundation for the development of an upcoming international therapeutic trial.

Figures